На этой странице перечислены больницы направления «Онкология» (включая Chemotherapy) в Дубай, ОАЭ, включая Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai.
Спросите нас о «Chemotherapy» в Дубай, ОАЭ
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 3 аккредитованных больниц (Онкология) в Дубай, ОАЭ
Рекомендуем🇦🇪 Burjeel Hospital for Advanced Surgery Dubai
Больница занимает 1-е место в этом списке по указанному рейтингу (4.5/5, 1 отзывов).
🇦🇪 Kings College Hospital Dubai
Больница занимает 2-е место в этом списке по указанному рейтингу (4.5/5, 1 отзывов).
🇦🇪 Aster Hospital Dubai
Больница занимает 3-е место в этом списке по указанному рейтингу (4.5/5, 1 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Онкология» указано среди её специализаций и она находится в Дубай, ОАЭ. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «chemotherapy» в Дубай, ОАЭ?
Выбор подходящей больницы для «chemotherapy» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Онкология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Chemotherapy»
Chemotherapy is a systemic cancer treatment using cytotoxic agents to destroy or inhibit the proliferation of malignant cells, administered as a curative, adjuvant, neoadjuvant, or palliative strategy depending on cancer type and stage. With response rates ranging from 60% to over 90% for highly chemosensitive malignancies such as Hodgkin lymphoma and testicular cancer, and meaningful disease control in solid tumors when combined with targeted or immunotherapy agents, chemotherapy remains a cornerstone of modern oncology. GAF Healthcare connects international patients with JCI- and NABH-accredited cancer centres in India and JCI- and DHA-licensed oncology hospitals in the UAE, providing end-to-end coordination so patients can access world-class systemic therapy at a fraction of Western costs. Hospital Stay: 0–3 days per cycle (most cycles are administered as day-care/outpatient infusions; inpatient stays apply for high-dose regimens or stem-cell-supported protocols) • Total Stay in Country (Fit-to-Fly): 1–6 weeks after the final cycle (dependent on nadir recovery, infection risk, and treating oncologist clearance; short-haul travel is often permitted between cycles) • Success Rate: 60–95% (disease- and stage-specific; e.g., >90% complete remission in Hodgkin lymphoma with ABVD; ~70–80% in early-stage breast cancer with AC-T; ~40–60% objective response in first-line NSCLC platinum doublets)
Clinical Overview
Chemotherapy encompasses a broad class of pharmacological agents—alkylating agents, antimetabolites, topoisomerase inhibitors, antimicrotubule agents, platinum analogues, and anthracyclines—each targeting specific vulnerabilities in the cell cycle to induce apoptosis or mitotic arrest in rapidly dividing cells. The physiological impact is systemic: while malignant cells are the primary target, rapidly proliferating normal tissues (bone marrow, gastrointestinal mucosa, hair follicles, and gonads) are also affected, giving rise to the characteristic toxicity profile including myelosuppression, mucositis, nausea, alopecia, peripheral neuropathy, and cardiotoxicity with certain agents such as doxorubicin or trastuzumab. Risk is stratified using validated tools including the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI), the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH), and ECOG/Karnofsky Performance Status, which guide dose intensity and supportive care planning. The standard of care in 2024–2025 integrates chemotherapy within multimodal oncology frameworks. In solid tumors, platinum-based doublets (carboplatin/paclitaxel, cisplatin/gemcitabine, FOLFOX, FOLFIRI) are combined with targeted agents such as bevacizumab, cetuximab, or pembrolizumab, with the specific backbone determined by molecular profiling including EGFR, ALK, KRAS, BRCA1/2, MSI-H, and TMB status. In hematologic malignancies, regimens such as R-CHOP (diffuse large B-cell lymphoma), ABVD/escalated BEACOPP (Hodgkin lymphoma), BEP (germ-cell tumors), and HyperCVAD (ALL) follow evidence-based NCCN and ESMO guidelines. Pharmacogenomic testing—including DPYD, TPMT, and UGT1A1 genotyping—is increasingly used at leading centres to personalize dosing and minimize life-threatening toxicities. Both India and the UAE have invested heavily in medical oncology infrastructure. Major Indian cancer centres operate linear accelerators, PET-CT suites, and dedicated hemato-oncology bone marrow transplant units, and their medical oncologists are frequently trained at MD Anderson, Memorial Sloan Kettering, or Royal Marsden. In Dubai and Abu Dhabi, facilities such as Mediclinic City Hospital, Cleveland Clinic Abu Dhabi, and Burjeel Medical City operate within JCI-accredited frameworks, offering fully integrated cancer programs with multidisciplinary tumor boards that align with NCCN and ESMO protocols.
Who is a Candidate?
• Newly diagnosed solid tumor patients (breast, lung, colorectal, gastric, ovarian, bladder, cervical, head & neck) requiring first-line, adjuvant, or neoadjuvant systemic therapy • Hematologic malignancy patients (lymphoma, leukemia, multiple myeloma) requiring induction, consolidation, or salvage chemotherapy • Patients with metastatic or locally advanced disease where chemotherapy is combined with immunotherapy (checkpoint inhibitors: pembrolizumab, nivolumab, atezolizumab) or targeted agents • Candidates for high-dose chemotherapy (HDC) with autologous stem cell rescue (ASCT) for relapsed/refractory lymphoma or multiple myeloma • Patients requiring intrathecal chemotherapy for CNS involvement or prophylaxis (e.g., methotrexate, cytarabine in ALL) • Patients with resectable tumors where neoadjuvant chemotherapy is intended to downstage disease prior to surgery (e.g., FLOT protocol for gastric cancer, NACT for locally advanced breast cancer) Required Pre-Treatment Diagnostics: • PET-CT scan (18F-FDG) for staging and treatment response assessment (Deauville criteria for lymphoma; RECIST 1.1 for solid tumors) • Biopsy with comprehensive immunohistochemistry (IHC), in-situ hybridization (FISH/ISH), and next-generation sequencing (NGS) panel for molecular profiling • Complete blood count with differential, comprehensive metabolic panel (renal and hepatic function), serum LDH, beta-2 microglobulin, tumor markers (CEA, CA125, AFP, beta-hCG, PSA as applicable) • Echocardiogram (ECHO) or MUGA scan (mandatory before anthracyclines; baseline LVEF must be ≥50%) • Pulmonary function tests (PFTs) before bleomycin-containing regimens • Audiometry before cisplatin-based therapy • DPYD, TPMT, UGT1A1 pharmacogenomic testing where applicable (5-FU, thiopurines, irinotecan) • Bone marrow biopsy for hematologic staging (lymphoma, leukemia, myeloma) • Brain MRI for CNS staging in high-risk histologies (DLBCL, SCLC, melanoma) • Fertility counseling and oocyte/sperm cryopreservation referral for premenopausal women and young men • COVID-19/infection screening and dental evaluation before high-dose or immunosuppressive regimens Contraindications and Relative Contraindications: • ECOG Performance Status ≥3–4 (poor functional status; consider palliative-intent dose reduction) • Severe renal impairment (eGFR <30 mL/min): cisplatin is contraindicated; carboplatin requires AUC-based dose adjustment (Calvert formula) • Hepatic impairment (Child-Pugh B/C): impaired metabolism of doxorubicin, vincristine, and paclitaxel necessitates dose modification or alternative agents • Severely depressed baseline bone marrow function (ANC <1,000/µL, platelets <75,000/µL) without correctable cause • Active severe infection or sepsis (defer until controlled) • LVEF <50% (relative contraindication for anthracyclines; reassess with cardio-oncology consultation) • Pregnancy (most cytotoxic agents are teratogenic in first trimester; select agents can be used in second/third trimester with multidisciplinary oversight) • Known severe hypersensitivity reactions to specific chemotherapy agents without viable alternatives
Treatment Options & Approaches
Chemotherapy is not a single treatment but a spectrum of regimens, delivery routes, and combination strategies, individualized based on tumor histology, molecular subtype, stage, comorbidities, and performance status. Standard Systemic Intravenous Chemotherapy: The foundation of most regimens. Multi-agent combinations are preferred over single agents to overcome drug resistance. Key backbone regimens include: AC-T (doxorubicin + cyclophosphamide followed by paclitaxel) for breast cancer; FOLFOX (5-fluorouracil + leucovorin + oxaliplatin) or FOLFIRI + bevacizumab/cetuximab for colorectal cancer; BEP (bleomycin + etoposide + cisplatin) for germ-cell tumors; R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) for DLBCL; ABVD (doxorubicin + bleomycin + vinblastine + dacarbazine) for Hodgkin lymphoma; and platinum doublets (carboplatin/paclitaxel ± pembrolizumab) for NSCLC. Cycles are typically administered every 2–3 weeks through a peripherally inserted central catheter (PICC line) or implantable port (Port-a-Cath), reducing venous access complications across 4–8 cycles. Dose-Dense and Dose-Intensified Regimens: Dose-dense AC-T (every 2 weeks with G-CSF support) has demonstrated superior disease-free survival in high-risk breast cancer compared to standard 3-weekly scheduling. Escalated BEACOPP is used for advanced-stage Hodgkin lymphoma in fit patients (age <60, ECOG 0–1) where superior tumor control outweighs increased toxicity. Dose intensity is managed with prophylactic G-CSF (filgrastim, pegfilgrastim) to prevent febrile neutropenia. High-Dose Chemotherapy with Autologous Stem Cell Transplantation (HDC-ASCT): Used in relapsed/refractory Hodgkin lymphoma (BEAM conditioning: carmustine + etoposide + cytarabine + melphalan), multiple myeloma (melphalan 200 mg/m² conditioning), and selected DLBCL. Stem cells are harvested after mobilization with G-CSF ± plerixafor, cryopreserved, and reinfused 24–72 hours after myeloablative conditioning. Leading Indian centres (Tata Memorial Hospital, Apollo, Fortis) and UAE centres (Cleveland Clinic Abu Dhabi, Burjeel) perform ASCT within dedicated BMT units with HEPA-filtered positive-pressure rooms. Targeted Therapy Combined with Chemotherapy: Molecular profiling drives combination strategies. HER2-positive breast cancer: trastuzumab + pertuzumab + docetaxel (TCHP). EGFR-mutant NSCLC: osimertinib (third-generation EGFR TKI) is now often preferred as monotherapy, but platinum-based doublets remain standard for EGFR-wild-type disease. Ovarian cancer: carboplatin + paclitaxel + bevacizumab, with PARP inhibitor maintenance (olaparib, niraparib) in BRCA-mutated patients. CML and Ph+ ALL: BCR-ABL TKIs (imatinib, dasatinib, ponatinib) combined with cytotoxic induction chemotherapy. Immunotherapy-Chemotherapy Combinations (Chemo-Immunotherapy): Checkpoint inhibitor combinations represent the most significant evolution in first-line oncology over the past decade. Pembrolizumab + carboplatin/paclitaxel for NSCLC (KEYNOTE-189/590). Atezolizumab + nab-paclitaxel for triple-negative breast cancer (PD-L1+). Nivolumab + FOLFOX for HER2-negative gastric/GEJ adenocarcinoma. These regimens require PD-L1 IHC scoring and, in some cases, MSI/TMB analysis to guide patient selection. Regional and Specialized Delivery Routes: Intraperitoneal (IP) chemotherapy (cisplatin + paclitaxel IP) is used in optimally debulked ovarian cancer following cytoreductive surgery. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) delivers heated cytotoxic agents (typically mitomycin-C or oxaliplatin at 41–43°C) directly into the peritoneal cavity during surgery for peritoneal surface malignancies (colorectal, appendiceal, gastric, ovarian). Intrathecal chemotherapy (methotrexate, cytarabine, hydrocortisone via lumbar puncture) treats or prevents CNS involvement in ALL, aggressive lymphomas, and leptomeningeal metastases. Hepatic arterial infusion (HAI) with floxuridine (FUDR) is used for colorectal liver metastases at specialized centres. Intravesical chemotherapy (mitomycin-C) is a standard adjunct after TURBT for non-muscle-invasive bladder cancer. Antibody-Drug Conjugates (ADCs): ADCs represent a precision evolution of chemotherapy: a cytotoxic payload is conjugated to a tumor-targeting antibody. Trastuzumab deruxtecan (T-DXd/Enhertu) for HER2-positive/low breast cancer and NSCLC; sacituzumab govitecan (Trodelvy) for triple-negative breast cancer and urothelial carcinoma; brentuximab vedotin (Adcetris) for CD30+ lymphomas; polatuzumab vedotin (Polivy) for DLBCL. These agents are now available at leading oncology centres in both India and the UAE.
Восстановление
Pre-Treatment Phase (Weeks 1–3 before Cycle 1): Step 1 — Remote Case Submission: Patient submits pathology reports, imaging (PET-CT, MRI, CT), operative notes, and prior treatment records to GAF Healthcare's oncology coordination team. A medical oncologist in India or the UAE performs a virtual consultation within 48–72 hours. Step 2 — Multidisciplinary Tumor Board Review: The treating centre convenes a tumor board (medical oncologist, radiation oncologist, surgical oncologist, pathologist, radiologist) to confirm diagnosis, review molecular profiling (NGS/IHC), and ratify the treatment regimen per NCCN/ESMO guidelines. Step 3 — Travel and Arrival: GAF Healthcare arranges the e-Medical visa (India) or UAE entry visa. The patient and one attendant arrive; airport transfer to accredited hospital or partner accommodation is coordinated. Step 4 — Baseline Work-Up (Day 1–3): Repeat or confirmatory imaging, blood panel, ECHO/PFTs/audiometry as required, pharmacogenomic testing, central venous access placement (PICC line or Port-a-Cath implant under local anesthesia), and a pre-chemotherapy anesthesia/cardiac risk assessment. Step 5 — Patient Education and Supportive Care Planning: Dietitian consultation (nutritional optimization, antiemetic dietary guidance), oncology nurse education on self-monitoring for fever/neutropenia, dental clearance, and fertility preservation referral if applicable. Chemotherapy Administration (Per Cycle): Step 6 — Cycle 1 (Day 1 of Treatment): Pre-medications administered IV (antiemetics: ondansetron, dexamethasone, aprepitant for highly emetogenic regimens; antihistamines and steroids for taxane hypersensitivity prophylaxis). Chemotherapy infusion administered in a dedicated oncology day-care unit under continuous nursing monitoring. Duration ranges from 1 hour (single-agent IV push) to 48–96 hours (continuous 5-FU infusion via ambulatory pump). Vital signs, allergic reactions, and infusion-related reactions are monitored in real time. Step 7 — Nadir Period (Days 7–14): The period of maximum myelosuppression. CBC is monitored at nadir (typically Day 10–14). G-CSF support (pegfilgrastim Day 2 of each cycle) is administered for dose-dense or high-risk regimens. Patients are educated on fever protocols (any temperature ≥38.3°C requires immediate hospital presentation for febrile neutropenia assessment and empiric broad-spectrum antibiotics). Step 8 — Cycle Recovery and Re-Assessment (Day 15–21): Blood counts recover; fitness for next cycle confirmed by ANC ≥1,500/µL and platelets ≥100,000/µL. Interim imaging (CT or PET-CT) performed after cycles 2–4 to assess treatment response (RECIST 1.1 / Deauville criteria). Multi-Cycle Regimen (Months 1–6): Step 9 — Cycles 2–8: Repeat administration per schedule (every 2 or 3 weeks). Between cycles, patients may be permitted to return home or stay in local accommodation coordinated by GAF Healthcare. GAF provides telemedicine access to the treating oncologist for symptom management and lab result review during intervals. End-of-Treatment Evaluation: Step 10 — Post-Treatment Restaging Scan (Week 2–4 after final cycle): PET-CT or CT chest/abdomen/pelvis for response assessment. Complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) determines subsequent management (surveillance, consolidation radiation, maintenance therapy, or salvage). Step 11 — Fit-to-Fly Clearance: The treating oncologist confirms bone marrow recovery (ANC ≥1,000/µL, no active infection, adequate renal/hepatic function). A discharge summary, treatment record, and next follow-up plan in the home country are provided. GAF Healthcare coordinates the return airport transfer and assists with medical record forwarding to the patient's home oncologist. Step 12 — Ongoing Remote Follow-Up: GAF Healthcare facilitates telemedicine follow-up consultations with the treating oncologist at 4–6 week intervals, coordinating local lab result upload and imaging review for patients who have returned home.
Возможные риски
Chemotherapy carries a well-characterized risk profile that is actively managed through evidence-based supportive care protocols at accredited centres. The most clinically significant acute risk is febrile neutropenia (FN): a potentially life-threatening infection occurring during the nadir period (Days 7–14), with an incidence of 10–40% depending on the regimen; the Multinational Association for Supportive Care in Cancer (MASCC) score is used to risk-stratify FN and guide inpatient versus outpatient antibiotic management. Myelosuppression (anemia, thrombocytopenia, leukopenia) is universal to varying degrees and is mitigated with growth factor support, blood transfusions, and platelet transfusions as required. Nausea and vomiting are effectively controlled in the majority of patients with modern triple-drug antiemetic regimens (NK1 antagonist + 5-HT3 antagonist + dexamethasone ± olanzapine). Cardiotoxicity is a serious concern with anthracyclines (doxorubicin, epirubicin): cumulative dose-dependent cardiomyopathy is monitored by serial ECHO or MUGA at defined dose thresholds; dexrazoxane is used as a cardioprotectant in select high-risk patients. Peripheral neuropathy (sensory greater than motor) develops in 30–70% of patients receiving platinum analogues (oxaliplatin, cisplatin) or taxanes (paclitaxel, docetaxel) and may persist beyond treatment completion; dose modification thresholds (NCI-CTCAE Grade 2–3) are strictly observed. Nephrotoxicity from cisplatin is managed with aggressive pre- and post-hydration protocols and avoidance in patients with eGFR <60 mL/min. Ototoxicity (high-frequency sensorineural hearing loss) is an irreversible risk of cisplatin, particularly at cumulative doses >400 mg/m²; audiometric monitoring is mandatory. Mucositis (oral and gastrointestinal) affects up to 40% of patients on 5-FU or methotrexate-based regimens and is managed with cryotherapy, keratinocyte growth factor (palifermin), and meticulous oral hygiene. Secondary malignancy (therapy-related myelodysplastic syndrome or acute myeloid leukemia) is a rare but recognized long-term risk of alkylating agents and topoisomerase II inhibitors. Reproductive toxicity (gonadal damage leading to premature ovarian insufficiency or azoospermia) is a critical survivorship consideration for younger patients, and fertility preservation referral prior to treatment initiation is a standard of care. Hypersensitivity reactions to taxanes and platinum agents are managed with standardized premedication protocols and, where required, rapid drug desensitization by experienced allergy-oncology teams. All of these risks are discussed transparently with patients during the pre-treatment multidisciplinary consultation coordinated by GAF Healthcare.
Почему GAF Healthcare
GAF Healthcare provides comprehensive end-to-end non-medical coordination for international patients undergoing chemotherapy in India or the UAE, removing the administrative and logistical burden from patients and their families during a demanding treatment journey. India — e-Medical Visa & Entry: GAF Healthcare prepares and submits the e-Medical Visa application on behalf of the patient and up to two attendants. The e-Medical Visa is issued electronically within 3–5 business days for most nationalities and permits multiple entries over 60 days (extendable up to 6 months), which is particularly important for patients undergoing multi-cycle chemotherapy regimens who may travel between cycles. GAF coordinates directly with the hospital's international patient services office to provide the official invitation letter required for the visa application. UAE — Visa & Entry: Patients from GCC countries and over 50 nationalities (including EU, UK, USA, Australia) enter the UAE visa-free or receive a visa on arrival valid for 30–90 days. Patients from other regions are assisted by GAF Healthcare in securing a UAE medical or tourist visa through official channels. Dubai and Abu Dhabi are served by international hub airports (DXB and AUH) with direct flights from virtually all global regions, making inter-cycle travel logistically straightforward. Airport Transfers & Ground Transportation: GAF Healthcare arranges private ambulance or premium vehicle transfers from the airport to the hospital or partner accommodation on all arrival and departure dates. For patients receiving outpatient day-care chemotherapy, dedicated transport between accommodation and the oncology center is organized for each infusion day. Accommodation for Patient and Attendant: GAF Healthcare has negotiated rates at vetted hotels, serviced apartments, and hospital-adjacent guesthouses in all major treatment cities (Mumbai, Delhi, Chennai, Bangalore, Hyderabad, Dubai, Abu Dhabi). Accommodation options are graded by proximity to the treating hospital, with furnished apartments recommended for families accompanying patients through multi-cycle regimens (4–24 weeks). All partner properties are selected for cleanliness, infection-control standards, and proximity to emergency care. Dedicated Case Manager and Interpreter: Each patient is assigned a dedicated GAF Healthcare case manager who serves as the single point of contact from remote consultation through discharge and home-country follow-up. Language interpreters (Arabic, Russian, Swahili, French, Bangla, and others) are available for consultations, consent processes, and daily communication with the medical team. Case managers accompany patients to major consultations when requested. Medical Record Coordination: GAF Healthcare's clinical team translates, summarizes, and transmits complete treatment records — including cycle-by-cycle chemotherapy administration records, toxicity logs, imaging reports, pathology, and the end-of-treatment response assessment — to the patient's home-country oncologist in a structured format compatible with international handover standards. Emergency Support: GAF Healthcare maintains a 24/7 emergency helpline for patients in-country. In the event of febrile neutropenia, severe adverse reaction, or any acute oncological emergency, the case manager coordinates immediate hospital admission and liaises with the treating oncology team.
Частые вопросы о процедуре «Chemotherapy»
What is the cost of chemotherapy in India compared to the UAE?
How long do I need to stay in the country before I am fit to fly home after chemotherapy?
What is the success rate of chemotherapy?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «chemotherapy» в Дубай, ОАЭ
Найдите лучшие больницы для «chemotherapy» в Дубай, ОАЭ
На этой странице представлено 3 больниц в Дубай, ОАЭ, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Chemotherapy» в Дубай, ОАЭ
Сколько больниц направления «Онкология» представлено в Дубай, ОАЭ?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Дубай, ОАЭ?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Chemotherapy» в Дубай, ОАЭ.
Свяжитесь с нами, если заметите неточность на этой странице.